Recombinant multi-species VEGFA/ MVCD1/ VEGF protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine VEGFA protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

The target: VEGFA, gene name: VEGFA, also named as MVCD1, VEGF, VPF. This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020].

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research.Please click inquiry for product quotation. → Inquiry

Catalog No.	Product Name	Species	Size	Price
GM-Tg-hg-T20761-Ag-1	Human VEGFA protein	Human	1mg/10mg/100mg/≥100mg	Inquiry
GM-Tg-rg-T20761-Ag-1	Rat VEGFA protein	Rat	1mg/10mg/100mg/≥100mg	Inquiry
GM-Tg-mg-T20761-Ag-1	Mouse VEGFA protein	Mouse	1mg/10mg/100mg/≥100mg	Inquiry
GM-Tg-cynog-T20761-Ag-1	Cynomolgus/ Rhesus macaque VEGFA protein	Cynomolgus/ Rhesus macaque	1mg/10mg/100mg/≥100mg	Inquiry
GM-Tg-felg-T20761-Ag-1	Feline VEGFA protein	Feline	1mg/10mg/100mg/≥100mg	Inquiry
GM-Tg-cang-T20761-Ag-1	Canine VEGFA protein	Canine	1mg/10mg/100mg/≥100mg	Inquiry
GM-Tg-bovg-T20761-Ag-1	Bovine VEGFA protein	Bovine	1mg/10mg/100mg/≥100mg	Inquiry
GM-Tg-bovg-T20761-Ag-1	Equine VEGFA protein	Equine	1mg/10mg/100mg/≥100mg	Inquiry
Shipping Cost:				760.00

Description

Catalog No.	GM-Tg-hg-T20761-Ag, GM-Tg-rg-T20761-Ag, GM-Tg-mg-T20761-Ag, GM-Tg-cynog-T20761-Ag, GM-Tg-felg-T20761-Ag, GM-Tg-cang-T20761-Ag, GM-Tg-bovg-T20761-Ag, GM-Tg-equg-T20761-Ag-1
Products Name	VEGFA protein
Species	Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name	VEGFA
Protein Sub-location	Secreted Protein/Potential Cytokines
Isotypes	Recombinant protein
Expression platform	Mammalian cell
Bioactivity validation	Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag	His
Products description	Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine VEGFA protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity	Purity: ≥95% (SDS-PAGE)
Application	In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation	Supplied as a 0.2 μM filtered solution of PBS, PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.